Skip to content
Inciteful Med

Treatments and Management: Blood Thinners and Antithrombin Therapy

Last updated:

Congenital antithrombin deficiency is managed using blood thinners like Warfarin or DOACs to prevent clots, and antithrombin concentrate during high-risk events or active clots. Patients who have had a clot typically need lifelong medication, while carriers may only need preventative care.

Key Takeaways

  • • Active blood clots are treated with blood thinners and may require an IV infusion of antithrombin concentrate if heparin resistance occurs.
  • • Patients who have experienced unprovoked blood clots usually require lifelong treatment with blood thinners like Warfarin or DOACs.
  • • Asymptomatic carriers who have never had a clot may only need preventative blood thinners during high-risk events like surgery, pregnancy, or travel.
  • • Estrogen-based birth control and hormone therapies are strictly unsafe because they significantly increase the risk of blood clots.
  • • Strictly adhering to your daily medication schedule is essential, as missing doses greatly increases the chance of a new clot forming.

Managing Congenital Antithrombin Deficiency is a lifelong commitment to reducing your risk of blood clots. Because this is the most potent inherited clotting disorder, your treatment plan will be highly individualized based on whether you have already had a clot or are an “asymptomatic carrier” (someone who has the gene but has never had a clot) [1][2].

Treatment for an Active Clot

If you develop a blood clot, the immediate goal is to stop it from growing and prevent it from traveling to your lungs.

  • Initial Treatment: Traditionally, this involves heparin (either an IV drip or an injection like Lovenox). However, because heparin requires antithrombin to work, you may experience heparin resistance, where standard doses are not effective [3][4].
  • Antithrombin Concentrate (ATc): In cases of severe clots or heparin resistance, doctors may give you an IV infusion of antithrombin concentrate to temporarily boost your levels and make your blood thinners work properly [5][6].
  • Alternative Medications: Doctors may use drugs like Argatroban or DOACs (Direct Oral Anticoagulants), which bypass the need for antithrombin entirely [4][7].

Long-Term Management

Once an acute clot is resolved, the focus shifts to preventing future ones.

  • Lifelong Anticoagulation: If you have had one or more “unprovoked” clots, your doctor will likely recommend lifelong blood thinners [8][9].
    • Warfarin (Coumadin): The traditional choice, requiring regular blood tests to monitor your levels.
    • DOACs (e.g., Eliquis, Xarelto): These are increasingly used because they do not require regular blood monitoring and have shown lower rates of major bleeding compared to older medications [10][11]. Important Note: DOACs are strictly contraindicated (not safe) during pregnancy and breastfeeding.
  • Asymptomatic Carriers: If you have the gene but have never had a clot, you may not need daily medication. Instead, you will use “prophylactic” (preventative) treatment only during high-risk times, such as surgery, pregnancy, or long-distance travel [12][13].

Important Safety Restrictions

There are specific situations that significantly increase your risk and must be avoided or managed carefully:

  • Hormonal Birth Control: Combined oral contraceptives containing estrogen are strictly contraindicated (not recommended) [14]. Estrogen naturally lowers antithrombin levels, which “doubles up” your risk in a dangerous way [15][16]. Safe alternatives include copper IUDs or certain progestin-only options [14][17].
  • Surgery and Hospitalization: Any time you are immobile or undergoing a procedure, your care team must have a plan for clot prevention, which often includes both blood thinners and antithrombin concentrate [18][19].

Adherence is Key

Because antithrombin deficiency carries a high risk of recurrence—up to 60% in some registries—strictly following your medication schedule is your best defense [20][21]. Missing doses can significantly increase the chance of a new clot forming [21].

Frequently Asked Questions

What is the treatment for a blood clot if I have antithrombin deficiency?
Treatment for an active clot typically involves blood thinners like heparin, DOACs, or Argatroban. If you experience heparin resistance, doctors may also administer an IV infusion of antithrombin concentrate (ATc) to help the blood thinners work effectively.
Will I need to take blood thinners for the rest of my life?
If you have had one or more unprovoked blood clots, your doctor will likely recommend lifelong blood thinners to prevent future clots. However, if you are an asymptomatic carrier who has never had a clot, you may only need medication during high-risk times like surgery or long-distance travel.
Are DOACs safe for people with antithrombin deficiency?
Direct Oral Anticoagulants (DOACs) like Eliquis or Xarelto are increasingly used for long-term management because they do not require regular blood monitoring. However, they are strictly contraindicated during pregnancy and breastfeeding.
Can I take birth control if I have an antithrombin deficiency?
Combined oral contraceptives that contain estrogen are strictly not recommended because estrogen naturally lowers antithrombin levels, significantly increasing your risk of a blood clot. Safe alternatives include copper IUDs or certain progestin-only options.
What is heparin resistance?
Heparin resistance occurs when standard doses of the blood thinner heparin are not effective at treating a clot. Because heparin relies on antithrombin to work in the body, people with antithrombin deficiency often experience this resistance and may need alternative medications or antithrombin concentrate.

Questions for Your Doctor

  • • Do you recommend lifelong anticoagulation for me, or should we use medication only during 'high-risk' events?
  • • Are DOACs (like Eliquis or Xarelto) a safe long-term option for my specific type of antithrombin deficiency?
  • • If I need surgery, what is the specific plan for using antithrombin concentrate (ATc)?
  • • Which types of birth control or hormone replacement therapies are safe for me to use?
  • • If I am hospitalized for an emergency, how should I inform the staff about my 'heparin resistance' risk?

Questions for You

  • • How consistent am I with taking daily medications? Would a once- or twice-daily pill be manageable for me?
  • • Have I experienced any unusual bleeding or bruising while on my current treatment?
  • • If I am an asymptomatic carrier, do I have a plan in place for upcoming 'high-risk' events like long-distance travel or minor procedures?
  • • Have I discussed my diagnosis with my close biological relatives so they can consider testing?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency.

    Bauer KA, Nguyen-Cao TM, Spears JB

    The Annals of pharmacotherapy 2016; (50(9)):758-67 doi:10.1177/1060028016651276.

    PMID: 27281301
  2. 2

    Prevalence, Genetic Background, and Clinical Phenotype of Congenital Thrombophilia in Chronic Thromboembolic Pulmonary Hypertension.

    Lian TY, Liu JZ, Guo F, et al.

    JACC. Asia 2022; (2(3)):247-255 doi:10.1016/j.jacasi.2022.02.010.

    PMID: 36338413
  3. 3

    Antithrombin Deficiency in Trauma and Surgical Critical Care.

    Ehrhardt JD, Boneva D, McKenney M, Elkbuli A

    The Journal of surgical research 2020; (256()):536-542 doi:10.1016/j.jss.2020.07.010.

    PMID: 32799002
  4. 4

    Heparin Resistance and Anticoagulation Failure in a Challenging Case of Cerebral Venous Sinus Thrombosis.

    King AB, O'Duffy AE, Kumar AB

    The Neurohospitalist 2016; (6(3)):118-21 doi:10.1177/1941874415591500.

    PMID: 27366296
  5. 5

    Investigation of real-world heparin resistance and anticoagulation management prior to cardiopulmonary bypass: report from a nationwide survey by the Japanese Association for Thoracic Surgery heparin resistance working group.

    Ito K, Sasaki K, Ono M, et al.

    General thoracic and cardiovascular surgery 2024; (72(1)):8-14 doi:10.1007/s11748-023-01936-5.

    PMID: 37195584
  6. 6

    Heparin Resistance During Surgical Resection of Inferior Vena Cava and Right Atrial Tumor Thrombus: A Case Report.

    Bello Dias MB, Mendes J, Gouveia J, et al.

    Revista portuguesa de cirurgia cardio-toracica e vascular : orgao oficial da Sociedade Portuguesa de Cirurgia Cardio-Toracica e Vascular 2017; (24(3-4)):199.

    PMID: 29701427
  7. 7

    A case report of atrial fibrillation in a patient with heparin resistance associated with an antithrombin III deficiency successfully treated by radiofrequency catheter ablation using a direct thrombin inhibitor.

    Kang H, Takemoto M, Tayama KI, Kosuga KI

    European heart journal. Case reports 2019; (3(1)):yty166 doi:10.1093/ehjcr/yty166.

    PMID: 31020242
  8. 8

    β-Antithrombin, subtype of antithrombin deficiency and the risk of venous thromboembolism in hereditary antithrombin deficiency: A family cohort study.

    Croles FN, Mulder R, Mulder AB, et al.

    Thrombosis research 2018; (168()):47-52 doi:10.1016/j.thromres.2018.06.004.

    PMID: 29902631
  9. 9

    Acute coronary syndrome in a young woman with antithrombin III deficiency.

    Fennich N, Salwa A, Nadia B, et al.

    Journal of cardiology cases 2013; (7(4)):e101-e103 doi:10.1016/j.jccase.2012.11.005.

    PMID: 30533135
  10. 10

    The Efficacy and Safety of DOACs in Inherited Antithrombin Deficiency: A Cohort Study from a Tertiary Referral Center.

    Dix C, Doyle AJ, Breen K, Hunt BJ

    Thrombosis and haemostasis 2025; (125(4)):379-384 doi:10.1055/a-2379-7288.

    PMID: 39102861
  11. 11

    Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry.

    Cohen O, Kenet G, Levy-Mendelovich S, et al.

    Journal of thrombosis and thrombolysis 2024; (57(4)):710-720 doi:10.1007/s11239-024-02957-4.

    PMID: 38491267
  12. 12

    Pregnancy-Related Venous Thromboembolism Risk in Asymptomatic Women With Antithrombin Deficiency: A Systematic Review.

    Rhéaume M, Weber F, Durand M, Mahone M

    Obstetrics and gynecology 2016; (127(4)):649-656 doi:10.1097/AOG.0000000000001347.

    PMID: 26959206
  13. 13

    Management of Venous Thromboembolism in Patients with Hereditary Antithrombin Deficiency and Pregnancy: Case Report and Review of the Literature.

    Refaei M, Xing L, Lim W, et al.

    Case reports in hematology 2017; (2017()):9261351 doi:10.1155/2017/9261351.

    PMID: 28168066
  14. 14

    Re-Examining Genetic Screening and Oral Contraceptives: A Patient-Centered Review.

    Hiedemann B, Vernon E, Bowie BH

    Journal of personalized medicine 2019; (9(1)) doi:10.3390/jpm9010004.

    PMID: 30650548
  15. 15

    Cost-effective screening strategy to prevent venous thromboembolism in combined oral contraceptive users.

    Douxfils J

    Frontiers in endocrinology 2025; (16()):1559162 doi:10.3389/fendo.2025.1559162.

    PMID: 40575268
  16. 16

    How I treat patients with hereditary antithrombin deficiency.

    Pabinger I, Thaler J

    Blood 2019; (134(26)):2346-2353 doi:10.1182/blood.2019002927.

    PMID: 31697819
  17. 17

    Isolated pulmonary embolism in a patient with progestin intrauterine device and factor V Leiden.

    Jean S

    Journal of community hospital internal medicine perspectives 2019; (9(3)):264-266 doi:10.1080/20009666.2019.1601059.

    PMID: 31258871
  18. 18

    Strategy for Cardiovascular Surgery in Patients with Antithrombin III Deficiency.

    Nishimura Y, Takagi Y

    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 2018; (24(4)):187-192 doi:10.5761/atcs.oa.18-00030.

    PMID: 29681597
  19. 19

    Perioperative Management of Hereditary Antithrombin Deficiency in a Patient Undergoing Minimally Invasive Thoracic Surgery: A Case Report.

    Domen H, Takakuwa Y, Yamada H

    Surgical case reports 2025; (11(1)) doi:10.70352/scrj.cr.25-0166.

    PMID: 41437950
  20. 20

    Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network.

    DeSancho MT, Suvar E, Roberts JC, et al.

    Journal of thrombosis and haemostasis : JTH 2024; (22(11)):3183-3190 doi:10.1016/j.jtha.2024.07.026.

    PMID: 39151704
  21. 21

    Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients.

    Undas A, Goralczyk T

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2017; (28(6)):438-442 doi:10.1097/MBC.0000000000000613.

    PMID: 28079536

This page provides informational content about congenital antithrombin deficiency treatments. Always consult your hematologist or healthcare provider before making changes to your blood thinner regimen.

Stay up to date

Get notified when new research about Hereditary thrombophilia due to congenital antithrombin deficiency is published.

No spam. Unsubscribe anytime.